CLINICAL TRIALS PROFILE FOR METFORMIN HYDROCHLORIDE; REPAGLINIDE

All Clinical Trials for METFORMIN HYDROCHLORIDE; REPAGLINIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00118950 ↗	Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet	Completed	Steno Diabetes Center	Phase 4	2001-03-01	Background: Metformin is the first drug of choice in obese patients with type-2 diabetes (T2DM) due to its antiglycaemic as well as its cardiovascular protective potentials. In non-obese T2DM patients insulin-secretagogues are empirically used as first choice. The aim of this study was to evaluate the effect of metformin versus an insulin-secretagogue, repaglinide on glycaemic regulation and non-glycaemic cardiovascular risk markers in non-obese patients with T2DM. Methods: Single-center, randomised, double-masked, double-dummy, cross-over-study of 96 non-obese (BMI ≤ 27 kg/m2) Caucasian T2DM-patients. After a one month run-in on diet-only treatment, patients were randomised to either repaglinide 2mg three times a day (t.i.d). followed by metformin 1g twice a day (b.i.d.) or vice versa each for a period of four months with a one month wash-out between interventions.
NCT00118950 ↗	Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet	Completed	Steno Diabetes Center Copenhagen	Phase 4	2001-03-01	Background: Metformin is the first drug of choice in obese patients with type-2 diabetes (T2DM) due to its antiglycaemic as well as its cardiovascular protective potentials. In non-obese T2DM patients insulin-secretagogues are empirically used as first choice. The aim of this study was to evaluate the effect of metformin versus an insulin-secretagogue, repaglinide on glycaemic regulation and non-glycaemic cardiovascular risk markers in non-obese patients with T2DM. Methods: Single-center, randomised, double-masked, double-dummy, cross-over-study of 96 non-obese (BMI ≤ 27 kg/m2) Caucasian T2DM-patients. After a one month run-in on diet-only treatment, patients were randomised to either repaglinide 2mg three times a day (t.i.d). followed by metformin 1g twice a day (b.i.d.) or vice versa each for a period of four months with a one month wash-out between interventions.
NCT00118963 ↗	Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes	Completed	Steno Diabetes Center	Phase 4	2003-01-01	Aim: The United Kingdom Prospective Diabetes Study (UKPDS) showed a reduction in cardiovascular events in obese patients with type-2-diabetes treated with metformin compared with other hypoglycaemic treatments with no difference in glycemic control between treatments. Non-obese patients with type-2-diabetes are usually treated with insulin-secretagogues or insulin when diet fails. Since non-obese patients with type-2-diabetes also carry a high risk of cardiovascular events, the use of metformin for this sub-group of patients might be more beneficial. Moreover, when insulin-treatment is initiated ongoing oral hypoglycaemic agents (OHA) are often continued, but in non-obese patients with type-2 diabetes little evidence exist for choosing the optimal class of OHA to be combined with insulin. The aim of the project is therefore to investigate the effect of metformin vs. an insulin-secretagogue (repaglinide) in combination with insulin on glycemic control and non-glycemic cardiovascular risk-factors in non-obese patients with type-2-diabetes, uncontrolled on diet alone. Methodology: Single-center, double-blind, double-dummy, randomized, parallel study involving 100 non-obese (BMI 27 kg/m2 or lower) patients with type-2-diabetes investigating the effect of treatment with metformin vs. repaglinide each in combination with biphasic insulin (Insulin-aspart 30/70, BIAsp30) for a period of 12 months.
NCT00118963 ↗	Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes	Completed	Steno Diabetes Center Copenhagen	Phase 4	2003-01-01	Aim: The United Kingdom Prospective Diabetes Study (UKPDS) showed a reduction in cardiovascular events in obese patients with type-2-diabetes treated with metformin compared with other hypoglycaemic treatments with no difference in glycemic control between treatments. Non-obese patients with type-2-diabetes are usually treated with insulin-secretagogues or insulin when diet fails. Since non-obese patients with type-2-diabetes also carry a high risk of cardiovascular events, the use of metformin for this sub-group of patients might be more beneficial. Moreover, when insulin-treatment is initiated ongoing oral hypoglycaemic agents (OHA) are often continued, but in non-obese patients with type-2 diabetes little evidence exist for choosing the optimal class of OHA to be combined with insulin. The aim of the project is therefore to investigate the effect of metformin vs. an insulin-secretagogue (repaglinide) in combination with insulin on glycemic control and non-glycemic cardiovascular risk-factors in non-obese patients with type-2-diabetes, uncontrolled on diet alone. Methodology: Single-center, double-blind, double-dummy, randomized, parallel study involving 100 non-obese (BMI 27 kg/m2 or lower) patients with type-2-diabetes investigating the effect of treatment with metformin vs. repaglinide each in combination with biphasic insulin (Insulin-aspart 30/70, BIAsp30) for a period of 12 months.

Clinical Trial Conditions for METFORMIN HYDROCHLORIDE; REPAGLINIDE

Condition Name

Condition Name for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Intervention	Trials
Diabetes Mellitus, Type 2	16
Diabetes	11
Type 2 Diabetes	3
Covid19	1

Condition MeSH

Condition MeSH for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Intervention	Trials
Diabetes Mellitus, Type 2	19
Diabetes Mellitus	16
Renal Insufficiency, Chronic	1
Kidney Diseases	1

Clinical Trial Locations for METFORMIN HYDROCHLORIDE; REPAGLINIDE

Trials by Country

Trials by Country for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Location	Trials
United States	41
China	14
United Kingdom	2
Belgium	2
Denmark	2

Trials by US State

Trials by US State for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Location	Trials
Florida	3
New York	2
Georgia	2
Texas	2
South Carolina	1

Clinical Trial Progress for METFORMIN HYDROCHLORIDE; REPAGLINIDE

Clinical Trial Phase

Clinical Trial Phase for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Clinical Trial Phase	Trials
Phase 4	12
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Clinical Trial Phase	Trials
Completed	18
Recruiting	2
Not yet recruiting	1

Clinical Trial Sponsors for METFORMIN HYDROCHLORIDE; REPAGLINIDE

Sponsor Name

Sponsor Name for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Sponsor	Trials
Novo Nordisk A/S	12
Steno Diabetes Center Copenhagen	2
Steno Diabetes Center	2

Sponsor Type

Sponsor Type for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Sponsor	Trials
Industry	16
Other	15

METFORMIN HYDROCHLORIDE; REPAGLINIDE Market Analysis and Financial Projection

Last updated: April 28, 2026

Clinical Trials Update and Market Projection: Metformin Hydrochloride and Repaglinide

What is the current clinical-trials landscape for metformin hydrochloride?

Metformin hydrochloride is a long-established oral antihyperglycemic used across type 2 diabetes (T2D) care. Clinical activity remains active because the molecule is used in broad patient phenotypes (early T2D, obesity-associated diabetes, chronic kidney disease, cardiovascular-risk cohorts) and as a comparator backbone in newer drug programs.

Trial activity pattern (high level)

• Ongoing studies tend to focus on:
  • Combination regimens (with GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, insulin strategies)
  • Dose optimization and tolerability in real-world and special populations
  • Cardiometabolic outcomes and biomarkers, often using older metformin as background standard of care
• Sponsors typically include global pharma, academic groups, and investigator-initiated networks rather than compound-development-only efforts.

Practical read-through

• Metformin is rarely “new drug launch critical,” but it is a “platform backbone” that absorbs clinical trial volume as background therapy.
• The most decision-relevant signal for investors is whether metformin-containing regimens demonstrate superior outcomes in subgroup endpoints, since those programs can expand patient penetration and formularies where metformin remains the default add-on or foundational therapy.

---

What is the current clinical-trials landscape for repaglinide?

Repaglinide is a short-acting meglitinide class insulin secretagogue used to lower postprandial glucose. Clinical development is comparatively lighter than metformin because repaglinide is mature, off-patent in most jurisdictions, and primarily supported by line-extensions, formulation work, and comparative effectiveness.

Trial activity pattern (high level)

• Studies typically target:
  • Repaglinide versus other short-acting strategies for meal-time control
  • Safety and tolerability in elderly populations and patients with variable meal patterns
  • Pharmacokinetic and formulation comparisons, including modified-release and fixed-dose combinations in some markets

Practical read-through

• Repaglinide’s clinical “update cycle” generally does not drive brand-level innovation at the molecule level.
• The market outcome is more linked to payer behavior, clinical guideline adherence to meal-targeted therapy, and generic availability than to large phase-outcome breakthroughs.

---

What do current market dynamics imply for metformin hydrochloride?

Metformin remains one of the highest-volume oral diabetes treatments globally. Competition centers on:

• Generic availability and price competition
• Fixed-dose combinations that keep metformin in product portfolios
• Formularies and guideline positioning as first-line therapy in T2D, often as the default entry point before add-ons

Market drivers

• Broad guideline alignment for early T2D management
• Low cost relative to newer agents
• Wide prescriber familiarity and broad dosing flexibility
• Persistent use as anchor therapy in combination regimens

Market headwinds

• Generic price compression across major markets
• Substitute pressure from earlier use of GLP-1 receptor agonists and SGLT2 inhibitors in some high-risk phenotypes
• Safety-management costs (GI tolerability, renal monitoring requirements) that increase clinician workload, even if the molecule remains standard

---

What do current market dynamics imply for repaglinide?

Repaglinide is smaller-market versus metformin and is more sensitive to:

• Prescribing preferences for meglitinides versus DPP-4 inhibitors, GLP-1 receptor agonists, and basal insulin strategies
• Payer restrictions and prior authorization policies in some regions
• Availability of low-cost generics that keep the product inside formulary but constrain unit economics

Market drivers

• Meal-time glucose targeting for patients with irregular meal patterns
• Use cases where hypoglycemia risk tolerance and postprandial control drive selection
• Generic penetration supporting broad access

Market headwinds

• Limited innovation at the active ingredient level
• Evolving guideline emphasis on other agent classes for specific patient-risk profiles
• Payer preference shifts toward once-daily oral options and injectables that can carry simpler adherence narratives

---

What is the projection outlook for metformin hydrochloride over the next 5 years?

For established generic molecules, “projection” is mainly a volume-and-share question, not a patent-driven revenue question. For metformin, the baseline expectation is:

• Volume: resilient, supported by guideline position and combination regimens that keep metformin in use
• Pricing: structurally constrained by generics, with modest erosion in many markets
• Total market: grows modestly at best in value terms, tracking diabetes prevalence and treatment intensification, with uneven regional patterns

Projection logic

• Diabetes prevalence trends support patient base growth.
• But incremental value growth is dampened by generic price dynamics.
• Combination products can partially offset price pressure, but those are still tied to generic economics for metformin.

---

What is the projection outlook for repaglinide over the next 5 years?

Repaglinide projections are more constrained by smaller addressable share and preference shifts:

• Volume: can hold steady or grow slightly where meal-pattern targeting is emphasized and meglitinides remain in formularies
• Pricing: remains constrained by generics and class-level substitution
• Total market: low single-digit growth in many scenarios; value stability more plausible than value expansion

Projection logic

• Repaglinide sits in a narrower therapeutic niche compared with metformin and newer injectables/orals.
• Clinical practice tends to move patients toward alternatives when broader glycemic control strategies are favored.

---

How do competitive and regulatory factors differ between metformin and repaglinide?

Competition structure

• Metformin: multi-manufacturer generic market with fixed-dose combo strategies that can keep metformin present even when add-on classes change.
• Repaglinide: smaller class market with generics; competition is usually cross-class (DPP-4 inhibitors, GLP-1 receptor agonists, insulin regimens) plus within-class (other meglitinides if present).

Regulatory exposure

• Both drugs face typical post-marketing requirements and labeling updates.
• Clinical development activity is less about approvals for new actives and more about labeling refinement and formulation or comparative data.

---

Where do the biggest commercial levers sit for investors and R&D leaders?

Metformin hydrochloride

• Fixed-dose combinations: maintain metformin presence while competing on adherence and tolerability
• Subpopulation outcomes: trials that support earlier intensification or renal-friendly use cases can improve penetration in guidelines and local formularies
• Evidence packaging: payer-facing endpoints that support cost-effectiveness relative to add-on therapies

Repaglinide

• Formulation and labeling: improvements that reduce dosing friction or improve tolerability can lift adoption in niche populations
• Payer strategy: defending formulary placement through pharmacoeconomic arguments tied to glycemic variability and hypoglycemia management
• Combination positioning: where feasible, combinations that simplify meal-time dosing can improve real-world persistence

---

Key Takeaways

• Metformin hydrochloride has persistent clinical-trial presence due to its role as foundational therapy and background comparator in combination and outcomes studies; market outlook is steady with value constrained by generics.
• Repaglinide shows lower molecule-level development intensity and is more sensitive to formulary placement and cross-class substitution; market outlook is stability with limited upside.
• For both products, the investment-relevant variable is not patent exclusivity but how combination strategies, payer policy, and subgroup evidence influence utilization.

---

FAQs

1) Are there meaningful new approvals expected for metformin or repaglinide as active ingredients?

Current activity patterns for mature molecules typically indicate incremental labeling, formulation, and combination-use studies rather than novel active-ingredient approval cycles.

2) What trial endpoints matter most for metformin’s commercial outlook?

Outcomes that support earlier intensification, tolerability in sensitive populations, and cost-effectiveness claims against add-on therapies influence payer access and adoption.

3) What endpoints matter most for repaglinide?

Postprandial glucose control, hypoglycemia rates, adherence proxies, and tolerability in older or variable-meal populations drive practical adoption.

4) Will combination products materially change market projections for metformin?

They can support volume persistence and modest value improvement in markets where fixed-dose adoption is incentivized, but they do not typically reverse generic price pressure at a system level.

5) How do generics affect long-term value projections for both drugs?

Generics compress unit prices and shift growth to volume and formulation mix, limiting sustained value CAGR even when total diabetes treatment volumes rise.

---

References

[1] International Diabetes Federation (IDF). Diabetes Atlas. IDF.
[2] American Diabetes Association (ADA). Standards of Care in Diabetes. ADA.
[3] European Association for the Study of Diabetes (EASD). EASD/ADA Consensus Reports on Management of Type 2 Diabetes. EASD.
[4] World Health Organization (WHO). Global report on diabetes. WHO.
[5] U.S. National Library of Medicine. ClinicalTrials.gov database records for metformin and repaglinide trials.